Wall Street analysts predict that The Cooper Companies, Inc. (NYSE:COO – Get Rating) will post sales of $824.78 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Cooper Companies’ earnings, with the highest sales estimate coming in at $854.66 million and the lowest estimate coming in at $811.10 million. Cooper Companies posted sales of $719.50 million during the same quarter last year, which suggests a positive year over year growth rate of 14.6%. The firm is scheduled to announce its next quarterly earnings report after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Cooper Companies will report full year sales of $3.32 billion for the current year, with estimates ranging from $3.29 billion to $3.42 billion. For the next year, analysts expect that the firm will post sales of $3.57 billion, with estimates ranging from $3.52 billion to $3.71 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Cooper Companies.
Cooper Companies (NYSE:COO – Get Rating) last released its quarterly earnings results on Thursday, March 3rd. The medical device company reported $3.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.14. Cooper Companies had a net margin of 31.00% and a return on equity of 9.89%. The business had revenue of $787.20 million for the quarter, compared to the consensus estimate of $739.30 million. During the same period in the previous year, the firm earned $3.17 EPS. The business’s revenue was up 15.7% on a year-over-year basis.
In related news, SVP Agostino Ricupati sold 5,607 shares of the business’s stock in a transaction dated Friday, March 18th. The stock was sold at an average price of $421.51, for a total transaction of $2,363,406.57. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gary S. Petersmeyer sold 300 shares of the business’s stock in a transaction that occurred on Monday, April 11th. The stock was sold at an average price of $410.55, for a total value of $123,165.00. The disclosure for this sale can be found here. Insiders have sold 19,646 shares of company stock valued at $8,195,614 over the last ninety days. 1.70% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ellevest Inc. lifted its stake in shares of Cooper Companies by 31.3% during the fourth quarter. Ellevest Inc. now owns 109 shares of the medical device company’s stock worth $46,000 after buying an additional 26 shares during the period. MAI Capital Management increased its stake in shares of Cooper Companies by 0.9% during the fourth quarter. MAI Capital Management now owns 3,236 shares of the medical device company’s stock worth $1,356,000 after purchasing an additional 28 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in Cooper Companies by 12.9% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 263 shares of the medical device company’s stock worth $110,000 after acquiring an additional 30 shares during the last quarter. Veritable L.P. boosted its holdings in Cooper Companies by 3.4% in the 1st quarter. Veritable L.P. now owns 972 shares of the medical device company’s stock valued at $406,000 after purchasing an additional 32 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC raised its stake in shares of Cooper Companies by 66.7% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 85 shares of the medical device company’s stock valued at $35,000 after acquiring an additional 34 shares during the period. Hedge funds and other institutional investors own 98.38% of the company’s stock.
Shares of NYSE:COO opened at $341.21 on Monday. Cooper Companies has a 1-year low of $309.43 and a 1-year high of $463.59. The stock has a market cap of $16.82 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.19 and a beta of 0.90. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.02 and a quick ratio of 0.67. The firm has a fifty day moving average price of $385.26 and a 200 day moving average price of $396.26.
Cooper Companies Company Profile (Get Rating)
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.
- Get a free copy of the StockNews.com research report on Cooper Companies (COO)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.